Series B second close · Biotech

Surv BioPharma raises ¥670 million in Series B second close

The additional financing brings the oncolytic-virus developer’s Series B total to ¥2.17 billion.

Surv BioPharma announced an additional ¥670 million in Series B financing on 23 December 2025, bringing the round’s total to ¥2.17 billion. The second close follows an earlier ¥1.5 billion close.

Participants included Innovation Kyoto 2021 Investment Limited Partnership, FFG Venture Fund III, Oita VC Success Fund No. 7, Sagin Venture Capital Fund No. 6, TOHO HOLDINGS CO and Fukuoka Jisho.

The Kagoshima University spinout plans to use the funding for nonclinical and clinical development of its oncolytic-virus therapies, including manufacturing investigational medicines.

Use of funds

Nonclinical and clinical development of oncolytic viruses, including manufacturing of investigational medicines

Funding history

Sources

  1. Surv BioPharma raises JPY670m in SeriesB second closesurvbiopharma.co.jp · Dec 23, 2025
  2. kyoto-unicap.co.jp
  3. oita-vc.blogspot.com
  4. sagabank.co.jp